Joshua M Shulman, M.D., Ph.D. Photo

Joshua M Shulman, M.D., Ph.D.

Baylor College of Medicine



Parkinson's Disease Center and Movement Disorders Clinic (Clinic)
Baylor College of Medicine Medical Center
McNair Campus
7200 Cambridge St., 9th Floor, MS: BCM609
Houston, Texas 77030
United States
(713) 798-2273
Google Maps


  • Post-Doctoral Fellowship at Brigham And Women's Hospital
    01/2012 - Boston, MA United States

  • Clinical Fellowship at Massachusetts General Hospital
    01/2010 - Boston, MA United States

  • Residency at Harvard Medical School Affiliate Hospitals
    01/2009 - Boston, MA United States

  • Internship at Massachusetts General Hospital
    01/2006 - Boston, MA United States

  • MD from Harvard Medical School
    01/2005 - Boston, MA United States

  • PhD from University Of Cambridge
    01/2000 - Cambridge, Cambridge United Kingdom

  • AB from Harvard College
    01/1997 - Cambridge, Massachusetts United States


  • English


  • Male

Professional Statement

Recent advances have made the discovery of genetic susceptibility loci for complex human phenotypes a reality, including nervous system disorders. The critical next step will be to definitively identify the responsible genes and understand their functions in both health and disease. Our research integrates genetic and genomic investigation in human subjects and model organisms, with the goal of understanding brain function and aging, and improving the treatment of neurologic disease. We focus on Alzheimer’s disease and Parkinson’s disease, two incurable neurodegenerative disorders and experimental paradigms for the age-dependent failure of brain cognitive and motor control in humans. Human Genetics: The clinical manifestation of neurodegenerative disease is the culmination of a multi-tiered pathogenic cascade that evolves over decades—understanding how genetic variants impact this causal chain is essential. We are therefore investigating the impact of genomic variation on directly measured Alzheimer’s and Parkinson’s disease pathology and related biomarkers, including quantitative measures of motor impairment based on assessments with biosensor devices. We are also deploying whole genome sequencing in the Alzheimer’s and Parkinson’s disease clinics and returning results to patients and families for precision medicine applications. Lastly, we are actively exploring links between inherited pediatric lysosomal disorders and risk for late-onset, adult neurodegenerative diseases. Drosophila Genetics: Despite the promise of current human genomic strategies, such as genome-wide association studies, next-generation sequencing and gene expression profiling, they often fail to definitively identify disease causal genes and variants. Therefore, we are taking advantage of the rapid and powerful genetics available in the fruit fly, Drosophila melanogaster, in order to accelerate the validation of responsible genes and understand relevant mechanisms in nervous system health and disease. Expression of human amyloid-beta Tau, or alpha-synuclein proteins in the fly nervous system recapitulates many core features of Alzheimer’s disease and Parkinson’s disease pathogenesis. We are testing candidate human susceptibility genes for functional genetic interactions in these fly models of neurodegeneration. Implicated molecular pathways are probed in greater depth, using both Drosophila as well as mouse and human cellular models for translation. Current areas of interest include endolysosomal sorting, RNA metabolism/splicing, neuronal cell adhesion and synaptic mechanisms of neurodegeneration.

Professional Interests

  • Functional genomics of Alzheimer's disease and Parkinson's disease
  • Integrative genetic analyses in humans and Drosophila
  • Movement Disorders
  • Neurogenetics

Physician Specialties

  • Neurology